and Leerink Swann LLC are acting as joint bookrunning managers for the offering, with Piper Jaffray & Co

Stifel and Piper Jaffray & Co

C$3.4 ($3.4) C$22.54 Idera Pharmaceuticals Inc. (Cambridge, Mass.; IDRA) 5/2/13 5/2/13 17.5S and W for 17.5S and 15.8S $0.50 and $0.49 45.1 Piper Jaffray $16.5 $22.55 Ironwood Pharmaceuticals Inc. (Cambridge, Mass.; IRWD)18 2/8/12 5/22/13 11 .2S $13 93.6 J.P. Morgan BofA Merrill Lynch (co-lead) Morgan Stanley (co-lead) Cowen and Co...MLV & Co. $60 Oncomed Pharmaceuticals Inc. (Redwood City, Calif.; OMED) 5/11/12 N/A N/A N/A Jefferies Leerink Swann (co-lead) Piper Jaffray BMO Capital Markets

Piper Jaffray & Co

and J.P. Morgan Securities LLC are acting as joint book-running managers, while Piper Jaffray & Co

Piper Jaffray analyst Ian Somaiya agreed, writing in a research report that AstraZeneca's decision "reflects the competitive nature of the RA market and the challenges fostamatinib would likely face gaining sufficient share to justify the $300 million in remaining milestone payments and 25 to 30 percent royalty on sales...Piper Jaffray's Somaiya was more optimistic, and wrote in research report that the Phase II data in DLBCL are expected in the second half of this year, which could "unlock a

Piper Jaffray analyst Edward Tenthoff noted that not only is the ARRY-380 deal a positive for Array, but the FDA's approval of GlaxoSmithKline's MEK inhibitor (trametinib) for metastatic melanoma provides validation for Array's two partnered MEK programs, which are due to report data at the upcoming American Society of Clinical Oncology (ASCO) meeting in Chicago

The trials were conducted under a special protocol assessment with the FDA. (See BioWorld Today, March 12, 2013.) Piper Jaffray analyst Edward Tenthoff wrote in a research report that his firm "had expected Omthera to seek a big pharma partner to conduct larger outcome trials to expand the label," which is exactly the strategy of AstraZeneca...Piper Jaffray's Tenthoff pointed out that Epanova is cheaper to make and purify than Vascepa

Those numbers may set the stage for a regulatory filing and a confirmatory, pivotal study in the U.S. – and possibly a partner, or a buyout, noted Piper Jaffray analyst Edward Tenthoff in a research report

Multiple Targeted Candidates Competing in CLL Still, idelalisib will face competition among cancer-targeting compounds, as Piper Jaffray & Co

Piper Jaffray and Co

Piper Jaffray analyst Ian Somaiya noted in a research report last week that "the Breo...After the approval, Piper Jaffray's Somaiya reiterated his rating on Theravance's shares

As Piper Jaffray analyst Ian Somaiya noted in a research report last month, there is "still no visibility into what went wrong," and neither Affymax nor Takeda has offered a timeline for concluding the investigation

In a research note last month, Piper Jaffray analyst Charles Duncan wrote that it "is likely to be something of a moving target in advance of launch

Shares/ Units (M) Price Shares Out (M)@ Lead, Other Underwriters Gross (US$M) Post- Offering Market Cap (M)% INITIAL OFFERINGS Chimerix Inc. (Research Triangle Park, N.C.; CMRX)1 3/8/13 4/11/13 7.32S $14 24.4 Morgan Stanley Cowen & Co. (co-lead) William Blair Lazard Capital Markets $102.5 $341.6 Omthera Pharmaceuticals Inc. (Princeton, N.J.; OMTH)2 3/8/13 4/12/13 8S $8 24.4 BofA Merrill Lynch Barclays (co-lead) Leerink Swann (co-lead) Stifel Piper Jaffray $64 $195.2 Tetraphase

Piper Jaffray analyst Edward Tenthoff anticipates launch this quarter, with Woodcliff Lake, N.J.-based Eisai hosting a sales force of about 200 representatives...With the anticipated launch milestone from Eisai, Piper Jaffray's Tenthoff said the firm should have "sufficient cash to reach profitability

Piper Jaffray & Co

BofA Merrill Lynch, Barclays and Leerink Swann acted as joint book-running managers, while Stifel and Piper Jaffray served as co-managers. (See BioWorld Today, April 2, 2013.)

Piper Jaffray's Somaiya was more optimistic